Detail publikace

Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients

POLANSKÁ, H. RAUDENSKÁ, M. HUDCOVÁ, K. GUMULEC, J. SVOBODOVÁ, M. HEGER, Z. FOJTŮ, M. BINKOVÁ, H. HORÁKOVÁ, Z. KOSTŘICA, R. ADAM, V. KIZEK, R. MASAŘÍK, M.

Originální název

Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients

Typ

článek v časopise ve Web of Science, Jimp

Jazyk

angličtina

Originální abstrakt

Approximately 90% of all head and neck tumors are squamous cell carcinomas. The overall survival of patients with head and neck squamous cell carcinoma (HNSCC) is low (≤50%). A non‑invasive marker of disease progression is sorely required. The present study focused on the plasmatic levels of epidermal growth factor receptor (EGFR) in HNSCC patients (N=92) compared with healthy (N=29) and diabetic [type 2 diabetes mellitus (T2DM); N=26] controls. Enzyme-linked immunosorbent assay using antibodies against the extracellular region of EGFR (L25‑S645) was performed. No significant changes were observed between diabetic and healthy controls. However, there were significantly higher EGFR plasma levels in HNSCC patients compared with both control groups (P=0.001 and 0.005, respectively). Receiver operating characteristic curve analysis identified a sensitivity of 76.09%, a specificity of 67.27% and an area under curve of 0.727 for this comparison. No significant association was observed between EGFR plasma levels and tumor stage, tumor grade, lymph node or distant metastasis occurrence, smoking habit or hypertension. However, the presence of human papillomavirus infection and T2DM in HNSCC patients had borderline effect on the plasma EGFR levels. Survival analysis revealed no significant influence of plasmatic EGFR levels on the overall and disease‑specific survival of HNSCC patients. In conclusion, EGFR plasma levels appear to be a relatively promising diagnostic, but poor prognostic, HNSCC marker.

Klíčová slova

spinocellular cancer, biomarker, EGFR, head and neck tumors, plasma, diagnosis

Autoři

POLANSKÁ, H.; RAUDENSKÁ, M.; HUDCOVÁ, K.; GUMULEC, J.; SVOBODOVÁ, M.; HEGER, Z.; FOJTŮ, M.; BINKOVÁ, H.; HORÁKOVÁ, Z.; KOSTŘICA, R.; ADAM, V.; KIZEK, R.; MASAŘÍK, M.

Vydáno

1. 9. 2016

ISSN

1792-1082

Periodikum

Oncology Letters

Ročník

12

Číslo

3

Stát

Řecká republika

Strany od

2127

Strany do

2132

Strany počet

6

BibTex

@article{BUT128503,
  author="Hana {Polanská} and Martina {Raudenská} and Kristýna {Hudcová} and Jaromír {Gumulec} and Markéta {Svobodová} and Zbyněk {Heger} and Michaela {Fojtů} and Hana {Binková} and Zuzana {Horáková} and Rom {Kostřica} and Vojtěch {Adam} and René {Kizek} and Michal {Masařík}",
  title="Evaluation of EGFR as a prognostic and diagnostic marker for head and neck squamous cell carcinoma patients",
  journal="Oncology Letters",
  year="2016",
  volume="12",
  number="3",
  pages="2127--2132",
  doi="10.3892/ol.2016.4896",
  issn="1792-1082"
}